WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP).
Authors:
Journal: Proceedings of the National Academy of Sciences of the United States of America
Publication Type: Journal Article
Date: 2007
DOI: PMC1783416
ID: 17213309
Abstract
Wiskott-Aldrich syndrome protein (WASP) is in a complex with WASP-interacting protein (WIP). WASP levels, but not mRNA levels, were severely diminished in T cells from WIP(-/-) mice and were increased by introduction of WIP in these cells. The WASP binding domain of WIP was shown to protect WASP from degradation by calpain in vitro. Treatment with the proteasome inhibitors MG132 and bortezomib increased WASP levels in T cells from WIP(-/-) mice and in T and B lymphocytes from two WAS patients with missense mutations (R86H and T45M) that disrupt WIP binding. The calpain inhibitor calpeptin increased WASP levels in activated T and B cells from the WASP patients, but not in primary T cells from the patients or from WIP(-/-) mice. Despite its ability to increase WASP levels proteasome inhibition did not correct the impaired IL-2 gene expression and low F-actin content in T cells from the R86H WAS patient. These results demonstrate that WIP stabilizes WASP and suggest that it may also be important for its function.
Chemical List
- Actins|||Boronic Acids|||Carrier Proteins|||Cytoskeletal Proteins|||Enzyme Inhibitors|||Interleukin-2|||Intracellular Signaling Peptides and Proteins|||Molecular Chaperones|||Proteasome Inhibitors|||Pyrazines|||WIPF1 protein, human|||Waspip protein, mouse|||Wiskott-Aldrich Syndrome Protein|||Bortezomib|||Arginine|||Calpain|||Proteasome Endopeptidase Complex
Reference List
- Bear JE, Rawls JF, Saxe CL. J Cell Biol. 1998;142:1325–1335.|||Derry JMJ, Ochs HD, Francke U. Cell. 1994;78:635–644.|||Miki H, Miura K, Takenawa T. EMBO J. 1996;15:5326–5335.|||Cannon JL, Labno CM, Bosco G, Seth A, McGavin MH, Siminovitch KA, Rosen MK, Burkhardt JK. Immunity. 2001;15:249–259.|||Sasahara Y, Rachid R, Byrne MJ, de la Fuente MA, Abraham RT, Ramesh N, Geha RS. Mol Cell. 2002;10:1269–1281.|||Gallego MD, Santamaria M, Pena J, Molina IJ. Blood. 1997;90:3089–3097.|||Ochs HD, Rosen FS. In: Primary Immunodeficiency Diseases: A Molecular and Cellular Approach. 2nd Ed. Ochs HD, Smith CIE, Puck JM, editors. New York: Oxford Univ Press; 2006. pp. 454–469.|||Snapper SB, Rosen FS, Mizoguchi E, Cohen P, Khan W, Liu C-H, Hagemann TL, Kwan S-P, Ferrini R, Davidson L, et al. Immunity. 1998;9:81–91.|||Ho HY, Rohatgi R, Lebensohn AM, Le M, Li J, Gygi SP, Kirschner MW. Cell. 2004;118:203–216.|||Martinez-Quiles N, Rohatgi R, Anton IM, Medina M, Saville SP, Miki H, Yamaguchi H, Takenawa T, Hartwig JH, Geha RS, Ramesh N. Nat Cell Biol. 2001;3:484–491.|||Ramesh N, Anton IM, Hartwig JH, Geha RS. Proc Natl Acad Sci USA. 1997;94:14671–14676.|||Volkman BF, Prehoda KE, Scott JA, Peterson FC, Lim WA. Cell. 2002;111:565–576.|||Anton IM, de la Fuente MA, Sims TN, Freeman S, Ramesh N, Hartwig JH, Dustin ML, Geha RS. Immunity. 2002;16:193–204.|||Jin Y, Mazza C, Christie JR, Gilliani S, Fiorini M, Mella P, Gandellini F, Stewart DM, Zhu Q, Nelson DL, et al. Blood. 2004;104:4010–4019.|||Stewart DM, Tian L, Nelson DL. J Immunol. 1999;162:5019–5024.|||Shcherbina A, Miki H, Kenney DM, Rosen FS, Remold-O'Donnell E. Blood. 2001;98:2988–2991.|||Oda A, Miyakawa Y, Druker BJ, Ishida A, Ozaki K, Ohashi H, Wakui M, Handa M, Watanabe K, Okamoto S, Ikeda Y. Blood. 1996;88:4304–4314.|||Suetsugu S, Hattori M, Miki H, Tezuka T, Yamamoto T, Mikoshiba K, Takenawa T. Dev Cell. 2002;3:645–658.|||Rengan R, Ochs HD. Rev Immunogenet. 2000;2:243–255.|||Noguchi M, Sarin A, Aman MJ, Nakajima H, Shores EW, Henkart PA, Leonard WJ. Proc Natl Acad Sci USA. 1997;94:11534–11539.|||Penna D, Muller S, Martinon F, Demotz S, Iwashima M, Valitutti S. J Immunol. 1999;163:50–56.|||Sarin A, Adams DH, Henkart PA. J Exp Med. 1993;178:1693–1700.|||Sato K, Kawashima S. Biol Chem. 2001;382:743–751.|||Selliah N, Brooks WH, Roszman TL. J Immunol. 1996;156:3215–3221.|||Lutskiy MI, Rosen FS, Remold-O'Donnell E. J Immunol. 2005;175:1329–1336.|||Strom TS, Gabbard W, Kelly PF, Cunningham JM, Nienhuis AW. Gene Ther. 2003;10:803–809.|||Aspenstorm P. Exp Cell Res. 2002;279:21–33.|||Ho HY, Rohatgi R, Ma L, Kirschner MW. Proc Natl Acad Sci USA. 2001;98:11306–11311.|||Kato M, Miki H, Kurita S, Endo T, Nakagawa H, Miyamoto S, Takenawa T. Biochem Biophys Res Commun. 2002;291:41–47.|||Ruiz-Vela A, Gonzalez de Buitrago G, Martinez AC. EMBO J. 1999;18:4988–4998.|||Deshpande RV, Goust JM, Chakrabarti AK, Barbosa E, Hogan EL, Banik NL. J Biol Chem. 1995;270:2497–2505.|||Sasaki T, Kikuchi T, Yumoto N, Yoshimura N, Murachi T. J Biol Chem. 1984;259:12489–12494.|||Zhang J, Shehabeldin A, da Cruz LA, Butler J, Somani AK, McGavin M, Kozieradzki I, dos Santos AO, Nagy A, Grinstein S, et al. J Exp Med. 1999;190:1329–1342.|||Gallego MD, de la Fuente MA, Anton IM, Snapper S, Fuhlbrigge R, Geha RS. Int Immunol. 2005;18:221–232.|||Anton I, Ramesh N, Geha RS. J Biol Chem. 1998;273:20992–20995.|||Kettner A, Kumar L, Anton IM, Sasahara Y, De La Fuente M, Pivniouk VI, Falet H, Hartwig JH, Geha RS. J Exp Med. 2004;199:357–368.|||Kawai S, Minegishi M, Ohashi Y, Sasahara Y, Kumaki S, Konno T, Miki H, Derry J, Nonoyama S, Miyawaki T, et al. J Immunol Methods. 2002;260:195–205.